Surveillance of healthcare associated pathogens in hospital/community settings

ISRCTN ISRCTN59966745
DOI https://doi.org/10.1186/ISRCTN59966745
Secondary identifying numbers NH001
Submission date
30/07/2013
Registration date
10/09/2013
Last edited
06/02/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Healthcare-associated infections are an important problem in hospitals and much research has been carried out on the bacteria that cause healthcare-associated infections (e.g. methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile) and the measures to control them. More recently, organisms that are resistant to many antibiotics, such as multi-drug resistant Gram-negative bacilli (MDR GNB) and vancomcyin-resistant enterococci (VRE), have become a problem in hospitals and are now a focus of research. In contrast, there has been little or no research done about healthcare-associated infections in community settings such as nursing homes. However, many people living in nursing homes are at risk of infection with these bacteria because of their underlying medical condition, antibiotic treatment, and contact with hospital either as an outpatient or an inpatient. The aim of this study is to look at the frequency of these organisms at Addenbrooke’s hospital and in the nursing home. This involves collection of samples for laboratory testing in order to identify the organisms that cause healthcare-associated infections (e.g. MRSA, C. difficile, MDR GNB and VRE). Genetic fingerprinting (whole genome sequencing) of the bacteria is also performed in order to understand the movement of organisms between patients and between the hospital and community setting.

Who can participate?
All patients admitted to Addenbrooke’s hospital and residents in a nursing home in Cambridge during the study period.

What does the study involve?
In the hospital, samples for testing are collected when indicated as part of routine clinical care. In the nursing home, samples are taken up to once a week for the duration of the study. The samples include swabs from the patient’'s nose, throat, groin, and any open wounds or ulcers. Samples of urine are also collected (if there is a urinary catheter) and stool (faeces). If a stool sample is not available then a rectal (bottom) swab is collected. Some clinical information is also collected from medical records. There are no study-specific interventions and all patients receive routine clinical care.

What are the possible benefits and risks of participating?
There are no direct benefits to the participant for taking part in the study. However, the information obtained from the study may help future patients and reduce the risk of healthcare-associated infections. There are no risks to the participant from taking part in the study. Having the samples taken may be mildly uncomfortable but does not hurt.

Where is the study run from?
The study is being run by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge (UK).

When is the study starting and how long is it expected to run for?
October 2013 to October 2014

Who is funding the study?
The Wellcome Trust and the Department of Health (UK)

Who is the main contact?
Professor Sharon Peacock
sjp97@medschl.cam.ac.uk

Contact information

Prof Sharon Peacock
Scientific

University of Cambridge
Department of Medicine
Box 157
Addenbrooke's Hospital
Hills Road
Cambridge
CB2 0QQ
United Kingdom

ORCiD logoORCID ID 0000-0002-1718-2782
Phone +44 (0)1223 336 867
Email sjp97@medschl.cam.ac.uk

Study information

Study designProspective observational cohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeScreening
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleA prospective surveillance study to define rates of carriage, transmission and infection by healthcare-associated pathogens in adjacent hospital and community settings
Study hypothesisTo determine the rates of carriage, transmission, and infection by specified healthcare-associated pathogens (MRSA, C. difficile, MDR GNB and VRE) in hospital and nursing home settings, using a combination of epidemiological investigation and bacterial whole genome sequencing.
Ethics approval(s)NRES committee: London Queen Square, 03/02/2014, ref: 13/LO/1278
ConditionHealthcare associated pathogens e.g. Methicillin resistant Staphylococcus aureus (MRSA), Clostridium difficile, multidrug resistant Gram negative bacteria (MDR GNB), vancomycin resistant enterococci (VRE)
InterventionA study of patients admitted to Addenbrooke's hospital and a nursing home during the one year study period.

The frequency of carriage and infection with healthcare-associated bacteria will be determined by microbiological testing. Transmission of healthcare-associated bacteria will be determined using bacterial whole-genome sequencing.
Intervention typeOther
Primary outcome measure1. Rate of carriage of MRSA, C. difficile, MDR GNB and VRE over time in hospital and nursing home populations
2. Rate of transmission of MRSA, C. difficile, MDR GNB and VRE over time within and between hospital and nursing home populations
3. Incidence of healthcare-associated infections by MRSA, C. difficile, MDR GNB and VRE over time in hospital and nursing home populations
Secondary outcome measuresNo secondary outcome measures
Overall study start date01/10/2013
Overall study end date01/10/2014

Eligibility

Participant type(s)Patient
Age groupAll
SexBoth
Target number of participants65,250
Participant inclusion criteria1. Inpatient at Addenbrooke’s hospital OR nursing home resident
2. Age 1 day to no upper age limit
3. Male or female
4. Microbiological testing for MRSA, C. difficile, MDR GNB, or VRE carriage or infection
Participant exclusion criteriaThe participant may not enter the study if they do not fulfil the inclusion criteria
Recruitment start date07/03/2014
Recruitment end date19/09/2014

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Cambridge
Cambridge
CB2 0QQ
United Kingdom

Sponsor information

Cambridge University Hospitals NHS Foundation Trust (UK)
Hospital/treatment centre

c/o Dr Stephen Kelleher
R&D Department
Box 277
Addenbrooke's Hospital
Hills Road
Cambridge
CB2 0QQ
England
United Kingdom

Phone +44 (0)1223 217418
Email stephen.kelleher@addenbrookes.nhs.uk
ROR logo "ROR" https://ror.org/04v54gj93

Funders

Funder type

Charity

The study is joint funded by the Wellcome Trust (reference: WT098600) and the Department of Health (reference: HICF-T5-342) through a Health Innovation Challenge Fund Grant

No information available

Results and Publications

Intention to publish date06/08/2017
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryOther
Publication and dissemination planOne further paper is currently under review.
IPD sharing planThe genome sequence data for the bacterial isolates publicly available after submitted to European Nucleotide Archive. Details provided in publication.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 12/01/2016 Yes No
Results article results 01/03/2016 Yes No
Results article results 01/08/2016 Yes No
Results article results 03/10/2016 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

06/02/2017: Publication references added.